血管内皮生长因子、胰岛素样生长因子-Ⅱ对肝细胞癌的诊断价值

了解血管内皮生长因子 (VEGF)、胰岛素样生长因子 -Ⅱ (IGF -Ⅱ )在肝细胞癌 (HCC)中的诊断意义。分别用双抗体夹心法 (ELISA)及放射免疫测定法 (RIA)测定了 35例肝细胞癌 (HCC)、16例肝硬化 (LC)和 16例慢性肝炎 (CH)及 10例正常对照者 (NC)的血清VEGF、IGF -Ⅱ水平。HCC患者血清VEGF、IGF -Ⅱ的水平明显高于正常对照组及其它各病组 (P <0 0 1或P <0 0 5 ) ,二者对于AFP阴性的HCC诊断阳性率分别为 6 3 6 %和 5 4 5 % ,三者联合检测可提高HCC诊断阳性率达 94 3%。有远处转移的HCC患者VEGF水平明显高于无转移者 (P <0 0 1)     

联合检测血清层粘蛋白、透明质酸、丙二醛及超氧化物歧化酶在肝病中的临床意义

联合检测肝病血清层粘蛋白(LN)、透明质酸(HA)、丙二醛(MDA)和超氧化物歧化酶(SOD)，并探讨其临床意义。采用放射免疫法和硫代巴比妥酸比色法检测肝病患者和正常对照组LN、HA、MDA和SOD含量的变化。肝硬化(LC)患者按Child-Pugh分级标准将肝功能分为A、B、C三级，其中18例行电子胃镜检查食道静脉曲张程度。急性肝炎(AH)组HA含量高于正常对照组(P＜0．001)差异显著，而LN变化不显著(P＞0．05)。慢性肝炎(CH)及肝硬化组HA、LN含量均明显高于对照组(P＜0．001)。LC组血清LN水平与食道静脉曲张程度呈正相关(r＝0．65，P＜0．01)。四项血清指标与肝硬化Child-Pugh分级的关系相一致。AH组MDA高于正常对照组(P＜0．01)，SOD低于正常对照组(P＜0．01)。CH组及比组MDA显著高于对照组(P＜0．002)，但SOD含量与正常对照组比较差异无显著性(P＞0．05)，LN、HA、MDA和SOD四项联合检测诊断LC的敏感性、特异性和诊断率分别为97．12％、97．32％、97．22％。四项联合检测是判断肝病损伤程度、病情发展、指导LC肝功能分级和诊断肝纤维化的良好的综合指标。     

糖尿病肾病患者血清肝细胞生长因子水平变化分析

目的 探讨肝细胞生长因子(HGF)在糖尿病肾病发生发展中的作用.方法 测定正常人、糖尿病组(单纯糖尿病组、微量白蛋白尿组、蛋白尿肾功能正常组、终末期肾功能衰竭组)共150例研究对象的血清HGF水平,并分析其与尿微量白蛋白等指标的关系.结果 糖尿病组血清HGF水平明显比正常对照组高(P＜0.05).糖尿病组中,微量白蛋白尿组和蛋白尿肾功能正常组两个亚组血清HGF水平明显比单纯糖尿病组高(P＜0.05),终末期肾功能衰竭组血清HGF水平明显比单纯糖尿病组高(P＜0.05),但低于微量白蛋白尿和蛋白尿肾功能正常组(P＜0.05).在出现终末期肾功能衰竭前HGF与尿微量白蛋白正相关(F=6.29、P＜0.05).结论 糖尿病患者随着肾损害的出现其HGF水平亦逐渐增高,但进入终末期肾功能衰竭后HGF水平明显降低.HGF与糖尿病肾病发生发展有关.     

应用实时荧光定量RT-PCR法建立肝癌分子诊断指数

目的: 筛选肝细胞癌(hepatocellular carcinoma,HCC)中表达水平较正常肝细胞差异大、特异性好的基因, 建立肝癌分子诊断指数, 以期从分子病因学角度实现对肝癌的早期诊断.方法: 随机选择38例手术切除组织标本, 其中正常肝5例、肝炎4例、肝硬化(LC)12例、HCC和癌旁组织17例, 实时荧光定量RT-PCR检测9个基因的表达, 以管家基因G3PDH为对照, 2-△△CT法计算目的基因相对表达量, 依据表达异常的基因个数建立分子诊断指数.结果: GPC3等6个基因在正常肝、肝炎、LC与HCC组的两组或多组间存在差异( P<0.05);GPC3、E2F1从肝炎组到LC、HCC组呈递增趋势, HGF、CLDN10在LC组表达量升高, 而在HCC组明显下降, PTEN、PRDM2、MGMT从肝炎组到LC、HCC组呈递减趋势; 9个基因在LC组分子诊断指数平均值为1.58, 在HCC组平均值为5.24, 二者差异显著; GPC3、E 2 F 1 、M M P 2 从癌旁到癌呈递增趋势,CLDN10、HGF、PTEN、DLC1、PRDM2、MGMT从癌旁到癌呈递减趋势.结论: 通过筛选更多基因的组合分析, 分子诊断指数有望成为鉴别诊断早期肝癌的一种有效方法.     

血清肝细胞生长因子测定对不稳定性心绞痛患者的临床意义

目的:探讨不稳定性心绞痛(UA)患者血清肝细胞生长因子(HGF)水平变化的临床意义.方法:用酶联免疫吸附法(ELISA)测定比较不稳定性心绞痛组(UA组,n=50)、稳定性心绞痛组(SA组,n=30)和对照组(n=30)心绞痛发作24小时内及治疗2周后血清HGF水平,其中UA组又根据冠状动脉(冠脉)造影时冠脉对硝酸甘油的反应分为有固定狭窄患者与无固定狭窄患者两部分.结果:UA组入院24小时内血清HGF水平比对照组和SA组均高[(1 674.54±1 450.03)pg/ml对(648.90±115.20)pg/ml和(728.53±288.14)pg/ml],有非常显著差异(P＜0.01),而且血清HGF水平与UA分型有关,UA组无固定狭窄患者血清HGF水平显著低于有固定狭窄患者[(848.44±146.49)对pg/ml(1 855.88±1 544.07)pg/m1,P＜0.01].UA组发病2周后血清HGF水平由(1 674.54±1 450.03)pg/ml下降至(880.71±201.75)pg/ml(P＜0.01);其中UA组在3个月内发生冠脉事件的5例患者2周后的血清HGF水平平均为(1 546.80±932.12)pg/ml,明显高于UA组患者的平均水平(880.71±201.75)pg/ml(P＜0.01).SA组经治疗后血清HGF水平变化不大(P＞0.05).结论:UA患者血清HGF动态升高;UA预后不良者血清HGF持续升高,血清HGF水平有可能成为临床上UA与SA鉴别以及对心绞痛危险分层的一个新的血清学指标.     

鸟氨酸氨甲酰基转移酶/丙氨酸氨基转移酶在肝细胞癌中的诊断价值

采用ELISA及速率法测定53例肝细胞癌(HCC组)、46例慢性肝炎(肝炎组)、42例肝硬化(肝硬化组)和50例健康体检者(对照组)血清鸟氨酸氨甲酰基转移酶(OCT)与丙氨酸氨基转移酶(ALT)比值,同时检测各组血清AFP水平.应用受试者工作特征曲线(ROC)对检查结果进行评价.结果HCC组血清OCT/ALT和AFP水平均高于其他三组(P均＜0.05).血清OCT/ALT和AFP的ROC曲线下面积分别为0.817和0.768;OCT/ALT的最优截断点约为3.2,灵敏度和特异度为69.8%和90.6%.AFP的最优截断点约为400 ng/ml,灵敏度和特异度分别为62.3%和84.9%.认为血清OCT/ALT值可作为鉴别诊断肝细胞癌的生化指标.     

长链非编码RNA ATB在丙肝相关性肝癌患者血清中的表达及临床意义

目的 探究丙肝相关性肝癌(HCC)患者血清中长链非编码RNA ATB(lncRNA-ATB)的表达水平及其在早期诊断中的价值。方法 收集2017年6月至2021年6月在空军军医大学第一附属医院门诊就诊的丙型病毒性肝炎(HCV)感染患者89例为研究对象,其中单纯慢性HCV(CH)患者28例,HCV相关肝硬化(LC)患者31例,HCV相关HCC患者30例;另选取30例同期的健康体检志愿者作为对照组。采用逆转录-聚合酶链反应(RT-PCR)测定LncRNA-ATB的表达水平,并通过受试者工作特征(ROC)曲线分析LncRNA-ATB表达水平在HCC诊断中的效能。结果 与对照组相比,LncRNA-ATB在CH组患者的表达水平无显著变化(P> 0.05),在LC组和HCC组的表达水平显著升高(P <0.001)。在CH组、LC组和HCC组中,随着肝病的进展,患者血清LncRNA-ATB的表达水平呈上升趋势(P <0.001);在区分HCC和LC患者时,血清LncRNA-ATB曲线下面积(AUC)为0.852(95%CI 0.749-0.954)。结论 LncRNA-ATB在HC...     

肝细胞癌患者血清瘦素水平与营养状况和预后的相关性

目的 探讨肝细胞癌(HCC)患者血清瘦素(Leptin)水平与营养状况和预后的相关性.方法 用ELISA法检测30例健康对照、31例肝硬化和168例HCC患者血清Leptin含量,分析HCC患者血清Leptin水平与营养和预后的关系.结果 HCC患者血清Leptin水平与体重指数(BMI)显著相关(P＜0.01),且显著低于肝硬化组和健康对照组(P＜0.05),女性均值高于男性1倍.HCC患者血清Leptin含量与肿瘤的大小显著相关(P＜0.01),Ⅲ、Ⅳ期患者显著低于健康对照(P＜0.01);随TNM 分期的增加和转移、复发,HCC患者血清Leptin水平明显降低(P＜0.05).结论 血清Leptin含量可反映HCC患者的BMI和营养状况,并可作为判断预后的指标.     

血清Talin-1在原发性肝细胞癌早期诊断中的作用

目的研究原发性肝细胞癌(hepatoce lloular carcinoma,HCC)患者血清中的踝蛋白1(Talin-1),并与传统的生物学标志物甲胎蛋白(alpha-fetoprotein,AFP)相比,探讨其在HCC早期诊断中的作用。方法采用酶联免疫吸附实验(enzyme linked immunosorbent assay,ELISA)分别检测120例血清样本中的Talin-1,包括HCC血清40例、肝硬化(liver cirrhosis,LC)血清40例、健康对照组血清40例。结果用ROC曲线创建一个Talin-1相对于AFP的诊断预测模型。HCC组Talin-1血清中的表达水平高于其他组(P0.05)。在HCC的诊断中,Talin-1诊断的准确性明显高于AFP相关的敏感性、特异性。结论 Talin-1在HCC的早期诊断中可能是一个潜在的标志物,并具有比传统的生物学标志物AFP更高的敏感性和特异性。     

神经生长因子在原发性肝癌中的表达及其临床意义

目的 观察神经生长因子(NGF)在原发性肝癌组织中的表达及在患者血清中的含量,了解血清NGF水平与肝癌临床病理特征的关系. 方法 26例肝细胞癌及对应癌旁组织,采用半定量PCR、免疫印迹及免疫组织化学分析NGF mRNA和蛋白的表达及其分布.健康对照者、慢性肝炎、肝硬化及肝癌患者共150例,采用酶联免疫吸附法(ELISA)检测血清NGF的水平,分析其临床意义.两组之间差异的显著性比较用t检验、Mann-Whitney U检验,多组之间差异的显著性比较应用Kruskal-Wallis H检验.数据均采用SPSS 11.5统计软件处理.结果 肝癌组织中NGF在mRNA及蛋白水平的表达高于癌旁组织,NGF主要分布于肝细胞胞质.血清NGF水平:肝癌组、肝硬化组、慢性肝炎组患者和正常对照组分别为(33.86±16.11)pg/ml、(20.57±9.73)pg/ml、(13.20±6.23)pg/ml和(11.13±6.12)pg/ml,肝癌组、肝硬化组显著高于慢性肝炎组患者和正常对照组,x2值分别为39.119和12.041,P值均＜0.01.肿瘤直径大于5cm及TNM分级为Ⅲ、Ⅳ级的肝癌患者血清NGF的水平高于肿瘤直径小于5cm及TNM分级为Ⅰ、Ⅱ级的患者.结论 NGF在肝癌组织中高表达,肝癌患者血清NGF水平明显升高,与肿瘤体积和TNM分级相关,提示NGF在肝癌的发生和发展过程中可能发挥一定作用,血清NGF有助于肝癌患者的病情评估和预后估计.     

Serum hepatocyte growth factor levels in liver diseases: Clinical implications

Although recent studies have shown that hepatocyte growth factor (HGF) is a potent mitogen in vivo, the significance of serum HGF in liver diseases remains unclear. To clarify clinical significance of serum HGF in liver diseases, serum HGF was measured in 127 patients with liver diseases and in 200 healthy individuals, using a highly sensitive immunoradiometric assay (IRMA). This assay is specific for HGF and is sensitive enough to detect 0.1 ng/mL of HGF. Mean values for serum HGF in acute hepatitis (AH), chronic hepatitis (CH), liver cirrhosis (LC), hepatocellular carcinoma (HCC), primary biliary cirrhosis (PBC), fulminant hepatic failure (FHF), and normal controls were 0.45, 0.40, 1.05,1.06, 0.44, 16.40, and 0.27 ng/mL, respectively. Serum HGF levels in these diseases were significantly increased compared with those in the controls (P < .001), and exhibited a positive correlation with total bilirubin, indocyanine green (ICG) test (R15), asparate aminotransferase (AST), and a negative correlation with albumin and prothrombin time (P < .001). Cirrhotic patients with modified Child class C had higher levels of serum HGF than those graded as modified Child class A or B (P < .001). In CH, serum HGF levels were significantly related to the histological activity index (HAI) score (P < .002). Seven patients with HCC who underwent transcatheter arterial embolization (TAE) exhibited a gradual increase in serum HGF levels up to day 4 after treatment; these higher levels were maintained until day 7, although AST reached a peak on day 2 and then decreased gradually. During clinical courses of patients with AH and CH, serum HGF was increased immediately after elevations of aminotransferases, and decreased as clinical symptoms improved. Serum HGF levels in survivors with FHF or AH were decreased during the illness (P = .0156), whereas serum HGF levels in nonsurvivors with FHF were increased. These findings suggest that serum HGF reflects the degree of liver dysfunction in chronic hepatic failure, and that serial measurement of serum HGF levels in acute hepatic injury serves as a prognostic factor.     

Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study

BACKGROUND: Hepatocyte growth factor (HGF) is a potent mitogen for hepatocytes in vivo as well as in vitro. Serum levels of HGF vary in liver diseases, reflecting liver damage and dysfunction. However there are no studies reporting expression of HGF and HGF receptor (c-met protein) simultaneously in various liver diseases. METHODS: To clarify the clinical significance of HGF/c-met protein expression in liver diseases, liver tissues from 62 patients consisting of 7 with acute hepatitis (AH), 20 with chronic hepatitis (CH), 9 with liver cirrhosis (LC) and 26 with hepatocellular carcinoma (HCC) were immunohistochemically examined. RESULTS: Intense staining of HGF was observed in patients from AH, CH and LC, although no immunoreactivity was seen in HCC. The expression of c-met protein was higher in patients with HCC and AH than in those with CH (p < 0.05). A correlation of immunoreactivity between HGF and c-met protein was not observed expect in patients with LC (p < 0.01). The extent of c-met expression had no correlation with differentiation of HCC, tumour size, presence of portal invasion, or serum AFP levels. CONCLUSION: The results of the present study suggest that HGF plays an important role in human liver diseases, mostly in a manner independent of c-met protein expression.     

Serum interleukin-8 levels in patients with hepatocellular carcinoma

Serum levels of interleukin-8 (IL-8) in 73 patients with hepatocellular carcinoma (HCC), 24 with liver cirrhosis (LC) and 18 with chronic hepatitis (CH), and in 20 healthy controls were measured by an enzyme-linked immunosorbent assay. The mean (± SD) level of serum IL-8 in patients with HCC was 48.4 ± 60.8 pg/ml, which were significantly (P < 0.01) higher than those in patients with LC (8.6 ± 8.6) and CH (2.7 ± 6.1), or that in controls (1.8 ± 5.8). It was revealed that serum IL-8 level was normalized after resection of HCC in patients whose serum IL-8 level had been high at the time of diagnosis. On the other hand, serum IL-8 levels were progressively increased with time in patients with HCC who had not received effective treatment. These findings suggest that IL-8 is produced by HCC cells in vivo, and serum IL-8 levels could be a marker for HCC. Moreover, significant correlation between serum IL-8 levels and the tumor sizes was found in patients with moderately differentiated HCC, which were mostly hypervascular on angiography. Serum IL-8 levels were significantly lower in patients with well-differentiated HCC than those with moderately differentiated HCC. Recent study demonstrated that IL-8 is an angiogenetic factor. Our present data thus suggest that IL-8 production from HCC may be involved in angiogenesis of this tumor.     

Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma

Aim: Hepatocellular carcinoma (HCC) is a common clinical problem all over the world. Fucosylated hemopexin (Fuc-Hpx) is a newly reported glycoprotein for the diagnosis of HCC, however, its clinical implications are unclear. The aim of this study was to elucidate the clinical utility of Fuc-Hpx in Japanese patients with HCC. Methods: The sera from 331 HCC patients, 45 with liver cirrhosis (LC), 85 with chronic hepatitis (CH) and 22 healthy people were examined for the expression of Fuc-Hpx; the level was compared with clinical parameters as well as hemopexin (Hpx) expression. The expressions of Fuc-Hpx in 12 HCC tissues and corresponding adjacent non-cancerous liver tissues were also examined. Results: No correlation was observed between Hpx and Fuc-Hpx level. The median Fuc-Hpx levels in healthy people and CH, LC and HCC patients were 3.8, 3.7, 6.1 and 7.6 AU/mL, respectively (CH vs LC, P = 0.002; CH vs HCC, P < 0.001; LC vs HCC, P = 0.02). Multivariate analysis revealed that low albumin, low prothrombin time and the presence of HCC were significantly correlated with high Fuc-Hpx (P = 0.013, =0.001 and <0.001, respectively). Among the HCC patients, albumin was correlated with high Fuc-Hpx; however, none of the tumor factors, such as tumor size, tumor number and tumor stage, was correlated with Fuc-Hpx level. The expression of Fuc-Hpx in cancer tissue was not different from that in non-cancerous tissue. Conclusion: Fuc-Hpx is a valuable biomarker for HCC but it might be a marker for hypercarcinogenic liver rather than a marker for tumor-bearing liver.     

Circulating microRNA,miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma

AIM: To explore the potential usefulness of serum miR-122 and miR-221 as non-invasive diagnostic markers of hepatitis C virus(HCV)-related hepatocellular carcinoma(HCC).METHODS: This prospective study was conducted on 90 adult patients of both sex with HCV-related chronic liver disease and chronic hepatitis C related HCC. In addition to the 10 healthy control individuals, patients were stratified into; interferon-na?ve chronic hepatitis C(CH)(n = 30), post-hepatitis C compensated cirrhosis(LC)(n = 30) and treatment-naive HCC(n = 30). All patients and controls underwent full clinical assessment and laboratory investigations in addition to the evaluation of the level of serum miR NA expression by RT-PCR.RESULTS: There was a significant fold change in serum mi RNA expression in the different patient groups when compared to normal controls; mi R-122 showed significant fold increasing in both CH and HCC and significant fold decrease in LC. On the other hand, mi R-221 showed significant fold elevation in both CH and LC groups and significant fold decrease in HCC group(P = 0.01). Comparing fold changes in miR NAs in HCC group vs non HCC group(CH and Cirrhosis), there was non-significant fold elevation in miR-122(P = 0.21) and significant fold decreasing in miR-221 in HCC vs non-HCC(P = 0.03). ROC curve analysis for miR-221 yielded 87% sensitivity and 40% specificity for the differentiation of HCC patients from non-HCC at a cutoff 1.82. CONCLUSION: Serum miR-221 has a strong potential to serve as one of the novel non-invasive biomarkers of HCC.     

Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis

Aim: To investigate the value of liver stiffness in diagnosing hepatocellular carcinoma (HCC) among patients with viral hepatitis, and to prospectively investigate relationships between liver stiffness and HCC development. Methods: Liver stiffness was measured by transient elastography for 157 patients with viral hepatitis, along with various other parameters potentially associated with HCC. HCC was initially present in 41 patients and absent in 116 patients, of whom 106 patients were followed prospectively for HCC development. Diagnostic performances of liver stiffness and other clinical parameters in predicting presence of HCC were evaluated using receiver operating characteristic (ROC) curves and area under the ROC curve (AUROC). Results: Liver stiffness was significantly higher in patients with HCC (24.9 ± 19.5 kPa) than in patients without HCC (10.9 ± 8.4 kPa; P < 0.0001). Age (P < 0.0001), platelet cell count (P = 0.0001), prothrombin activity (P = 0.0009), alpha fetoprotein (P = 0.0091), and des‐gamma‐carboxy prothrombin (DCP) (P = 0.0099) also differed significantly between patients with and without HCC. The largest AUROC was for liver stiffness. Differences between liver stiffness and age, platelet cell count, prothrombin activity, and DCP were not significant, but the AUROC of liver stiffness was superior to that of alpha fetoprotein (P = 0.03850). Using a cut‐off liver stiffness of 12.5 kPa, development of HCC was identified in 10 of the 106 patients followed. Multivariate analysis identified liver stiffness ≥12.5 kPa, age ≥60 years, and serum total bilirubin ≥1.0 mg/dL as significantly correlated with development of HCC. Conclusions: Liver stiffness as measured by transient elastography is a predictor of HCC development in viral hepatitis.     

肝硬化和肝癌患者体内铜含量变化及其临床意义

采用原子吸收分光光度法等对肝硬化和肝癌患者体内铜含量（Ｃｕ）和血清铜蓝蛋白（Ｃｐ）进行了测定。结果表明：①肝硬化患者血清Ｃｐ和尿Ｃｕ高于正常人（Ｐ＜０．０５和０．０１）。②肝癌患者血清Ｃｕ与Ｃｐ呈一致性升高；尿Ｃｕ明显升高且与血请Ｃｕ呈正相关（ｒ＝０．５６７，Ｐ＜０．０１）。③硬化肝Ｃｕ与癌周组织（有肝硬化改变）相近并高于正常肝和肝癌组织。④肝硬化和肝癌组头发Ｃｕ均明显低于对照组（Ｐ＜０．０１）。⑤大肝癌患者血清Ｃｕ明显高于小肝癌患者（Ｐ＜０．０５）。⑥治疗后肝癌缩小与血清Ｃｕ降低相一致。⑦血清Ｃｕ和Ｃｐ可作为诊断肝癌、特别是甲胎蛋白（ＡＦＰ）阴性肝癌的辅助指标，前者亦可作为判断疗效的参考指标。     

原发性肝细胞癌血清中miR-888-5p的表达及临床意义

背景miR-888-5p高表达于原发性肝细胞癌(hepatocellular carcinoma,HCC)组织及HCC细胞系,可促进肿瘤细胞侵袭及转移,与疾病分期及预后不良相关.然而HCC患者血清中miR-888-5p的表达水平尚未被检测,血清miR-888-5p对于HCC诊断及预后判断相关价值尚未被评估.目的检测HCC患者血清中miR-888-5p表达水平,探究其对HCC的诊断价值及与临床特征之间的关系.方法收集68例HCC患者、46例慢性乙型病毒性肝炎(chronic hepatitis B,CHB)患者、43例肝硬化(liver cirrhosis,LC)患者及40例同期健康体检者,实时荧光定量聚合酶链反应(quantitative real-time polymerase chain reaction,qRT-PCR)法检测血清中miR-888-5p表达量,受试者工作特征(receiver operating characteristic,ROC)曲线评估其诊断HCC的价值,并分析与HCC临床特征之间的关系.结果HCC患者血清中miR-888-5p表达量较CHB、LC及健康者显著上调(P<0.05).ROC曲线提示,联合检测ROC曲线下面积(area under curve,AUC)为0.907,敏感性91.18%,特异性72.50%)对HCC诊断价值优于分别检测血清miR-888-5p(AUC=0.737,敏感性79.41%,特异性62.50%)及甲胎蛋白(alpha-fetoprotein,AFP)(AUC=0.819,敏感性73.53%,特异性97.50%),且对AFP阴性HCC也具有较高的诊断价值:AUC=0.793,敏感性90.90%,特异性62.50%.此外,miR-888-5p表达水平与HCC肺转移相关(P=0.01).结论血清miR-888-5p对HCC及AFP阴性HCC具有较高诊断价值,与AFP联合检测诊断价值更高.miR-888-5p表达水平与HCC肺转移相关,有望成为HCC早期诊断及评估预后的新型血清学分子标志物.